What Happened?
Shares of clinical research company IQVIA (NYSE: IQV) jumped 15.9% in the morning session after the company reported second-quarter financial results that beat Wall Street expectations and raised its full-year profit guidance.
The company announced second-quarter revenue of $4.02 billion, which surpassed analyst estimates of $3.96 billion. Adjusted earnings per share (EPS), a key measure of profitability, came in at $2.81, which was also ahead of the consensus forecast of $2.77. The strong performance was driven by solid growth across its business segments, with the Technology & Analytics Solutions division seeing an 8.9% revenue increase. Looking ahead, IQVIA updated its full-year 2025 guidance. It slightly raised its forecast for adjusted EPS to a range of $11.75 to $12.05. The company also reaffirmed its full-year revenue projection, expecting between $16.1 billion and $16.3 billion. The positive results and optimistic outlook appeared to boost investor confidence, signaling robust demand for its clinical research and data analytics services.
Is now the time to buy IQVIA? Access our full analysis report here, it’s free.
What Is The Market Telling Us
IQVIA’s shares are not very volatile and have only had 8 moves greater than 5% over the last year. Moves this big are rare for IQVIA and indicate this news significantly impacted the market’s perception of the business.
IQVIA is down 4.6% since the beginning of the year, and at $186.21 per share, it is trading 26% below its 52-week high of $251.55 from August 2024. Investors who bought $1,000 worth of IQVIA’s shares 5 years ago would now be looking at an investment worth $1,133.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.